Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.06 -0.65%

-$0.02 today

Market cap
$106.78M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.02M

Average 0.04M

CLLS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Cellectis S.A.NASDAQ: CLLS

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows in line with its trailing trend

Q1 FY2026 research & development of $23.09M rose 5.3% year over year, in line with the +5.0% change in trailing-twelve-month research & development. Sequentially, it fell 5.5% from the prior quarter. Over 3 fiscal years it compounded at -1.4% a year.

Context

  • Research & development amounted to 128.2% of revenue in FY2025, down 89.9 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +5.3% holds above the trailing-twelve-month pace of +5.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$23.09M-5.5% QoQ
Last fiscal yearDec 2025
$93.52M+3.3% YoY
LTMMar 2026
$94.68M+5.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.3%——
1 year+3.3%——
3-year CAGR-1.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
93.52M USD
Year-over-year change
+3.3%
4-year CAGR
-5.6%

Research & Development vs competitors

How CLLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +5.0% is the 5th highest of 10, against a peer median of -6.9%.
  • Research & development amounts to 139.0% of revenue for CLLS, versus a peer median of 1530.1%.
CLLS Competitors
Research & Development for CLLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$152.7M USD+75.7%+85.3%—
DBVTDBV Technologies S.A.LTM Mar 2026$124.71M USD+42.2%+15.6%—
CLLSCellectis S.A.LTM Mar 2026$94.68M USD+5.0%-1.4%139.0%
SLNSilence Therapeutics plcLTM Mar 2026$61.84M USD—+24.0%6710.8%
KRROKorro Bio, Inc.LTM Mar 2026$58.79M USD-15.8%+15.8%1530.1%
ANROAlto Neuroscience, Inc.LTM Mar 2026$55.94M USD+19.0%+24.4%—
ACIUAC Immune S.A.LTM Mar 2026CHF 52.18M CHF-17.6%-2.2%1409.6%
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$35.87M USD+29.3%+13.9%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$20.65M USD-58.3%-18.4%—
AMRNAmarin Corporation plcLTM Mar 2026$18.45M USD-6.9%-13.3%8.6%
MREOMereo BioPharma Group plcLTM Mar 2026$18.13M USD-12.8%-16.7%3625.8%
Peer median (excluding CLLS) —-6.9%+14.7%1530.1%

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.35M19.17M755K41.51M72.95M
Cost of Revenue1.84M8.48M7.42M9.18M9.8M
Gross Profit28.5M10.69M(6.66M)32.32M63.15M
Gross Margin93.9%55.7%-882.6%77.9%86.6%
Research & Development117.84M97.5M87.65M90.54M93.52M
Selling, General & Admin22.88M8.9M8.12M8.42M8.6M
Operating Expenses131.98M100.35M90.64M91.88M96.23M
Depreciation & Amortization14.16M18.44M18.52M19.85M20.06M
EBITDA(78.43M)(76.38M)(92.64M)(9.46M)(39.85M)
EBITDA Margin-258.4%-398.4%-12269.8%-22.8%-54.6%
Operating Income(103.48M)(89.67M)(97.3M)(59.55M)(33.08M)
Operating Margin-341.0%-467.7%-12887.7%-143.5%-45.3%
Interest Income719K1.12M3.61M11.28M9.5M
Interest Expense4.37M3.79M5.31M7.45M8.11M
Other Income / Expenses6.73M(8.94M)(19.16M)22.79M(34.94M)
Income Before Tax(96.75M)(98.6M)(116.46M)(36.76M)(68.02M)
Pre-Tax Margin-318.8%-514.3%-15425.7%-88.6%-93.2%
Income Tax Expense(3K)87K371K0(423K)
Net Income(114.2M)(106.14M)(101.06M)(36.76M)(67.59M)
Net Margin-376.3%-553.6%-13385.3%-88.6%-92.7%
EPS (Basic)(1.93)(2.33)(1.77)(0.41)(0.68)
EPS (Diluted)(1.93)(2.33)(1.77)(0.41)(0.68)
Weighted Avg Shares44.82M45.55M57.01M90.57M100.28M
Weighted Avg Shares (Diluted)44.82M45.55M57.01M90.57M100.28M

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.